慢性炎症性脱髄性多発ニューロパシー（CIDP）の世界市場 2020年

• 英文タイトル：Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：GIR201113867 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本書では、慢性炎症性脱髄性多発ニューロパシー（CIDP）の世界市場を調査対象にし、慢性炎症性脱髄性多発ニューロパシー（CIDP）の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（コルチコステロイド療法、IVIG治療、血漿交換療法、免疫抑制薬療法、免疫調節療法、その他）、用途別分析（病院、神経科専門クリニック、研究及び学術研究所）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Teijin Pharma、Grifols、Octapharma、Shire、Kedrion、Pfizer、Bio Products Laboratory、Mitsubishi Tanabe Pharma Corporation、Momenta Pharmaceuticals、CSL Behring (CSL Limited)、Baxter、MedDay Pharmaceuticals、GeNeuro Pharmaceuticals ・企業別売上、市場シェア ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の地域別市場分析 ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・慢性炎症性脱髄性多発ニューロパシー（CIDP）のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・慢性炎症性脱髄性多発ニューロパシー（CIDP）のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の種類別市場規模2015-2020：コルチコステロイド療法、IVIG治療、血漿交換療法、免疫抑制薬療法、免疫調節療法、その他 ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の用途別市場規模2015-2020：病院、神経科専門クリニック、研究及び学術研究所 ・慢性炎症性脱髄性多発ニューロパシー（CIDP）の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論

Market Overview
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market has been segmented into:
Corticosteroid Therapy
IVIG Treatment
Plasma Exchange Therapy
Immunosuppressive Drug Therapy
Immunomodulator Therapy
Other

By Application, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) has been segmented into:
Hospital
Specialist Neurology Clinic
Research and Academic Laboratories

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market presented in the report. This section sheds light on the sales growth of different regional and country-level Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market.

The report offers in-depth assessment of the growth and other aspects of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Analysis
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales, revenue and market share for each player covered in this report.

The major players covered in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are:
Teijin Pharma
Grifols
Octapharma
Shire
Kedrion
Pfizer
Bio Products Laboratory
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals
CSL Behring (CSL Limited)
Baxter
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals

レポート目次

---

Table of Contents

1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
1.1 Product Overview and Scope of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.2 Classification of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Type
1.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type in 2019
1.2.3 Corticosteroid Therapy
1.2.4 IVIG Treatment
1.2.5 Plasma Exchange Therapy
1.2.6 Immunosuppressive Drug Therapy
1.2.7 Immunomodulator Therapy
1.2.8 Other
1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by Application
1.3.1 Overview: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Specialist Neurology Clinic
1.3.4 Research and Academic Laboratories
1.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by Regions
1.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Status and Prospect (2015-2025)
2 Company Profiles
2.1 Teijin Pharma
2.1.1 Teijin Pharma Details
2.1.2 Teijin Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Teijin Pharma SWOT Analysis
2.1.4 Teijin Pharma Product and Services
2.1.5 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Grifols SWOT Analysis
2.2.4 Grifols Product and Services
2.2.5 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Octapharma
2.3.1 Octapharma Details
2.3.2 Octapharma Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Octapharma SWOT Analysis
2.3.4 Octapharma Product and Services
2.3.5 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Shire
2.4.1 Shire Details
2.4.2 Shire Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Shire SWOT Analysis
2.4.4 Shire Product and Services
2.4.5 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.5 Kedrion
2.5.1 Kedrion Details
2.5.2 Kedrion Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Kedrion SWOT Analysis
2.5.4 Kedrion Product and Services
2.5.5 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Pfizer SWOT Analysis
2.6.4 Pfizer Product and Services
2.6.5 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.7 Bio Products Laboratory
2.7.1 Bio Products Laboratory Details
2.7.2 Bio Products Laboratory Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Bio Products Laboratory SWOT Analysis
2.7.4 Bio Products Laboratory Product and Services
2.7.5 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.8 Mitsubishi Tanabe Pharma Corporation
2.8.1 Mitsubishi Tanabe Pharma Corporation Details
2.8.2 Mitsubishi Tanabe Pharma Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Mitsubishi Tanabe Pharma Corporation SWOT Analysis
2.8.4 Mitsubishi Tanabe Pharma Corporation Product and Services
2.8.5 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.9 Momenta Pharmaceuticals
2.9.1 Momenta Pharmaceuticals Details
2.9.2 Momenta Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Momenta Pharmaceuticals SWOT Analysis
2.9.4 Momenta Pharmaceuticals Product and Services
2.9.5 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.10 CSL Behring (CSL Limited)
2.10.1 CSL Behring (CSL Limited) Details
2.10.2 CSL Behring (CSL Limited) Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 CSL Behring (CSL Limited) SWOT Analysis
2.10.4 CSL Behring (CSL Limited) Product and Services
2.10.5 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.11 Baxter
2.11.1 Baxter Details
2.11.2 Baxter Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Baxter SWOT Analysis
2.11.4 Baxter Product and Services
2.11.5 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.12 MedDay Pharmaceuticals
2.12.1 MedDay Pharmaceuticals Details
2.12.2 MedDay Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 MedDay Pharmaceuticals SWOT Analysis
2.12.4 MedDay Pharmaceuticals Product and Services
2.12.5 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
2.13 GeNeuro Pharmaceuticals
2.13.1 GeNeuro Pharmaceuticals Details
2.13.2 GeNeuro Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 GeNeuro Pharmaceuticals SWOT Analysis
2.13.4 GeNeuro Pharmaceuticals Product and Services
2.13.5 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Market Share
3.2.2 Top 10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Market Share by Regions
4.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
4.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
4.5 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
5 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries
5.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
5.2 USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
5.3 Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
5.4 Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
6 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries
6.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
6.2 Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
6.3 UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
6.4 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
6.5 Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
6.6 Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries
7.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
7.2 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
7.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
7.4 Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
7.5 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
8 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries
8.1 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
8.2 Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
8.3 Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Countries
9.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
9.3 UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
9.4 Egypt Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
9.5 South Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Market Share by Type (2015-2020)
10.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Type (2019-2024)
10.3 Corticosteroid Therapy Revenue Growth Rate (2015-2025)
10.4 IVIG Treatment Revenue Growth Rate (2015-2025)
10.5 Plasma Exchange Therapy Revenue Growth Rate (2015-2025)
10.6 Immunosuppressive Drug Therapy Revenue Growth Rate (2015-2025)
10.7 Immunomodulator Therapy Revenue Growth Rate (2015-2025)
10.8 Other Revenue Growth Rate (2015-2025)
11 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment by Application
11.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2015-2020)
11.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Specialist Neurology Clinic Revenue Growth (2015-2020)
11.5 Research and Academic Laboratories Revenue Growth (2015-2020)
12 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast (2021-2025)
12.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast (2021-2025)
12.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast by Regions (2021-2025)
12.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
12.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
12.6 South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Teijin Pharma Corporate Information, Location and Competitors
Table 6. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 7. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 8. Teijin Pharma SWOT Analysis
Table 9. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 10. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Grifols Corporate Information, Location and Competitors
Table 12. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 13. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2018-2019)
Table 14. Grifols SWOT Analysis
Table 15. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 16. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Octapharma Corporate Information, Location and Competitors
Table 18. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 19. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 20. Octapharma SWOT Analysis
Table 21. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 22. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Shire Corporate Information, Location and Competitors
Table 24. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 25. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 26. Shire SWOT Analysis
Table 27. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 28. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Kedrion Corporate Information, Location and Competitors
Table 30. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 31. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 32. Kedrion SWOT Analysis
Table 33. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 34. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Pfizer Corporate Information, Location and Competitors
Table 36. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 37. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 38. Pfizer SWOT Analysis
Table 39. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 40. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Bio Products Laboratory Corporate Information, Location and Competitors
Table 42. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 43. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 44. Bio Products Laboratory SWOT Analysis
Table 45. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 46. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Mitsubishi Tanabe Pharma Corporation Corporate Information, Location and Competitors
Table 48. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 49. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 50. Mitsubishi Tanabe Pharma Corporation SWOT Analysis
Table 51. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 52. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Momenta Pharmaceuticals Corporate Information, Location and Competitors
Table 54. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 55. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 56. Momenta Pharmaceuticals SWOT Analysis
Table 57. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 58. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. CSL Behring (CSL Limited) Corporate Information, Location and Competitors
Table 60. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 61. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 62. CSL Behring (CSL Limited) SWOT Analysis
Table 63. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 64. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Baxter Corporate Information, Location and Competitors
Table 66. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 67. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 68. Baxter SWOT Analysis
Table 69. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 70. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. MedDay Pharmaceuticals Corporate Information, Location and Competitors
Table 72. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 73. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 74. MedDay Pharmaceuticals SWOT Analysis
Table 75. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 76. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. GeNeuro Pharmaceuticals Corporate Information, Location and Competitors
Table 78. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Business
Table 79. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Revenue (USD Million) (2017-2018)
Table 80. GeNeuro Pharmaceuticals SWOT Analysis
Table 81. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product and Solutions
Table 82. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) by Players (2015-2020)
Table 84. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Players (2015-2020)
Table 85. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) by Regions (2015-2020)
Table 86. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Regions (2015-2020)
Table 87. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
Table 88. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Table 89. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) by Countries (2015-2020)
Table 90. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) by Countries (2015-2020)
Table 91. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Countries (2015-2020)
Table 92. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Table 93. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) by Countries (2015-2020)
Table 94. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Table 95. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) by Type (2015-2020)
Table 96. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Type (2015-2020)
Table 97. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Forecast by Type (2021-2025)
Table 98. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Application (2015-2020)
Table 99. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Application (2015-2020)
Table 100. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Forecast by Application (2021-2025)
Table 101. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Picture
Figure 2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type in 2019
Figure 3. Corticosteroid Therapy Picture
Figure 4. IVIG Treatment Picture
Figure 5. Plasma Exchange Therapy Picture
Figure 6. Immunosuppressive Drug Therapy Picture
Figure 7. Immunomodulator Therapy Picture
Figure 8. Other Picture
Figure 9. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application in 2019
Figure 10. Hospital Picture
Figure 11. Specialist Neurology Clinic Picture
Figure 12. Research and Academic Laboratories Picture
Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 14. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Players in 2019
Figure 21. Global Top 5 Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share in 2019
Figure 22. Global Top 10 Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share in 2019
Figure 23. Key Players Market Share Trend
Figure 24. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 25. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Regions (2015-2020)
Figure 26. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Regions in 2018
Figure 27. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 28. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 29. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 30. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 31. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 32. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Figure 33. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries in 2019
Figure 34. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 35. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 36. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 37. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Figure 38. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries in 2019
Figure 39. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 40. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 41. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 42. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 43. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Figure 45. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries in 2019
Figure 46. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 47. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 48. Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 49. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 50. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 51. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Figure 52. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries in 2019
Figure 53. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 54. Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 55. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries (2015-2020)
Figure 56. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Countries in 2019
Figure 57. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 58. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 59. Egypt Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 60. South Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue and Growth Rate (2015-2020)
Figure 61. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Type (2015-2020)
Figure 62. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Type in 2019
Figure 63. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Forecast by Type (2021-2025)
Figure 64. Global Corticosteroid Therapy Revenue Growth Rate (2015-2020)
Figure 65. Global IVIG Treatment Revenue Growth Rate (2015-2020)
Figure 66. Global Plasma Exchange Therapy Revenue Growth Rate (2015-2020)
Figure 67. Global Immunosuppressive Drug Therapy Revenue Growth Rate (2015-2020)
Figure 68. Global Immunomodulator Therapy Revenue Growth Rate (2015-2020)
Figure 69. Global Other Revenue Growth Rate (2015-2020)
Figure 70. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Application (2015-2020)
Figure 71. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Application in 2019
Figure 72. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Forecast by Application (2021-2025)
Figure 73. Global Hospital Revenue Growth Rate (2015-2020)
Figure 74. Global Specialist Neurology Clinic Revenue Growth Rate (2015-2020)
Figure 75. Global Research and Academic Laboratories Revenue Growth Rate (2015-2020)
Figure 76. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 77. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 78. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share Forecast by Regions (2021-2025)
Figure 79. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
Figure 80. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
Figure 81. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
Figure 82. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
Figure 83. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Forecast (2021-2025)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel

---